Request Trial
metamorworks / Shutterstock.com
17 July 2026NewsRegulation & IndustryMarisa Woutersen

Why is 2026 already a record year for M&A activity?

Blockbuster acquisitions are back, impacting the pharma industry at record pace. As billions flow into breakthrough science, LSIPR’s series explores what’s driving the surge, how today’s deals are done, and where IP makes the difference.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Regulation & Industry
UK to clamp down on non-compete clauses and long notice periods
13 October 2026   Potential reforms to post-employment restrictions and contractual notice periods could make it harder for brand owners to protect trade secrets and manage staff departures, prompting questions about how businesses can safeguard their interests.
Regulation & Industry
AIPPI World Congress: ‘Diversity need not be an obstacle to unity’
9 October 2026   As the AIPPI World Congress returned to Germany for the first time in nearly half a century, it heard calls for greater international cooperation and legal harmonisation, highlighting why diversity matters for the future of IP and brand owners.
Regulation & Industry
Roche, Marques counsel: The fight against ‘deadly’ counterfeits is a race for the newest and best tech
5 October 2026   Tapio Blanc, chief trademark officer at Roche, explains why fighting fakes can be a matter of life and death, and how AI, online platforms, and ‘mousetrap buys’ are affecting brand protection.


Editor's picks

Boston Scientific expands dispute with J&J unit over cardiac-access technology
MedTech
Boston Scientific expands dispute with J&J unit over cardiac-access technology
12 October 2026

Editor's picks

MedTech
Boston Scientific expands dispute with J&J unit over cardiac-access technology
12 October 2026
In-house counsel
WATCH: Genevant IP director on tackling UPC-EPO opposition divide
1 October 2026
Pharma
Lilly loses Fed Circ rehearing bid, sparking enablement questions
1 October 2026
Pharma
Takeda sees off UK challenge to Elvanse SPC
28 September 2026
Pharma
Behind the case: How Novartis defended its blockbuster Entresto in the UK
22 September 2026
Regulation & Industry
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
17 September 2026

More features

Haynes Boone expands in California with new office
Accord’s generic hopes dashed in cyanide antidote ruling
Novo’s semaglutide protection weakens after European ruling
UK to clamp down on non-compete clauses and long notice periods
Boston Scientific expands dispute with J&J unit over cardiac-access technology
Brazilian firm appoints patent strategist to lead department
AIPPI World Congress: ‘Diversity need not be an obstacle to unity’
Novartis pursues Apotex over copies of $2bn skin cancer drug franchise